New Study to Assess the Efficacy of Ivermectin Against COVID-19
Barcelona, 14 May 2020
- Clínica Universidad de Navarra and the Barcelona Institute for Global Health (ISGlobal), a centre supported by the ”la Caixa” Foundation, have launched a clinical trial to investigate the efficacy of ivermectin against COVID-19.
- The aim of the study, carried out in collaboration with Idifarma, is to determine whether administration of ivermectin is associated with a shorter viral clearance time.
- “Ivermectin has been shown to have an antiviral effect against other single-chain RNA viruses, including dengue and yellow fever, and it has successfully inhibited the replication of those viruses in vitro,” explained Carlos Chaccour, a specialist affiliated with Clínica Universidad de Navarra and ISGlobal and principal investigator for the new study.